August 2026 in “Dermatology and Therapy” The study involving 1,226 participants examined the dermatologic effects of weight management treatments, particularly glucagon-like peptide 1-receptor agonists (GLP-1RAs). It found that greater weight loss was associated with increased reports of negative aesthetic impacts such as skin sagging, facial volume loss, and hair shedding. Specifically, among those losing more than 20% of body weight, 72% reported skin sagging and 52% reported hair loss. However, improvements were noted in preexisting inflammatory and hormonally driven skin conditions like hidradenitis suppurativa and acanthosis nigricans. The findings highlight the need for further research into the mechanisms and incidence of these outcomes with GLP-1RA treatments.
April 2026 in “Open MIND” GLP-1 medications can cause skin and muscle issues, but treatments like ultrasound and PRP can help.
June 2026 in “Annals of Clinical Pathology” Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
April 2026 in “Journal of Clinical Medicine” GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
June 2026 in “Dermatology and Therapy” GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
Herbal supplements like Berberine, Cinnamon, and Fenugreek may be affordable alternatives for managing PCOS.
Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.
May 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient education and personalized care.
2 citations
,
January 2025 in “Cutis” Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.
1 citations
,
September 2025 in “Dermatology and Therapy” GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
February 2026 in “Editora Pasteur eBooks” A comprehensive, personalized approach is needed for treating female pattern hair loss and obesity, involving multiple medical disciplines and lifestyle changes.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Tailored medication preparation and ongoing education are crucial for effective treatments.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.
68 citations
,
January 2022 in “International Journal of Molecular Sciences” PCOS management includes lifestyle changes and medications, with ongoing research into repurposed drugs for better treatment options.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
29 citations
,
September 2023 in “Journal of Clinical Medicine” Semaglutide helps obese PCOS patients lose weight and improve health.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
4 citations
,
March 2025 in “Journal of Cosmetic Dermatology” Semaglutide may cause hair loss, but more research is needed to confirm this.
1 citations
,
September 2025 in “Medicina Moderna - Modern Medicine” Combining lifestyle changes with personalized medication is crucial for better managing obesity in PCOS.
August 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” Rapid weight loss from weight-loss drugs, not the drugs themselves, mainly causes hair loss.
July 2026 in “Journal of Investigative Dermatology” GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.
July 2026 in “Journal of the American Academy of Dermatology” GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.
May 2026 in “Pharmaceuticals” Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.
April 2026 in “Science Progress” GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
October 2025 in “Brazilian Journal of Hair Health” Hair loss from weight-loss treatments is usually temporary and reversible.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.